赛诺菲、Regeneron开发PCSK9新药alirocumab临床试验击败Zetia

2014-11-21 佚名 生物谷

赛诺菲公司和Regeneron公司联合开发的用于降低有害胆固醇的药物alirocumab最近又取得了新进展。公司表示在治疗他汀类药物不耐患者的临床研究中,alirocumab表现优异,击败了默沙东的Zetia。这也使得alirocumab有望成为新型心脏病药物进入市场。 此次赛诺菲公司和Regeneron公司进行的临床三期研究中共招募了360名患者,实验数据显示,alirocumab治疗组的

赛诺菲公司和Regeneron公司联合开发的用于降低有害胆固醇的药物alirocumab最近又取得了新进展。公司表示在治疗他汀类药物不耐患者的临床研究中,alirocumab表现优异,击败了默沙东的Zetia。这也使得alirocumab有望成为新型心脏病药物进入市场。

此次赛诺菲公司和Regeneron公司进行的临床三期研究中共招募了360名患者,实验数据显示,alirocumab治疗组的LDL胆固醇水平降低了45%,同时有42%的患者LDL胆固醇水平降低至标准水平;而Zetia治疗组中这两个数字分别仅为14.6%和4%。这一结果也大大增加了alirocumab获得FDA批准的可能性。赛诺菲公司和Regeneron公司的研究人员已经将这一研究结果在美国心脏病学会上公布。而今年早些时候,安进公司开发的同类药物evolocumab也取得了出色的研究成果。这两种药物都是一种能够阻断PCSK9蛋白的抗体类药物。通过阻断PCSK9,药物能够帮助机体清除血液中的LDL胆固醇。而分析人士预计这一市场规模大约在100亿美元左右。本周早些时候,默沙东公司Zetia研究数据证明了降低LDL胆固醇含量能够帮助心脏病患者延长生存期,降低心脏病发病概率。这一结果无疑将极大刺激PCSK9药物市场的扩大。

不过,现在还不能确定谁将成为这一市场的最大赢家,因为安进公司、辉瑞公司也在这一领域有着类似产品。且它们的研究数据表现差相仿佛。因此分析人士预测,PCSK9市场不太可能出现一家独大的场景,而更可能是三足鼎立的局面。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1685566, encodeId=249d1685566d1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Mar 25 22:30:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777226, encodeId=6c151e77226ab, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Mon Nov 24 06:30:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911669, encodeId=92df1911669f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 19 02:30:00 CST 2015, time=2015-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968029, encodeId=fab5196802915, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15269, encryptionId=9e5e15269a8, topicName=Regeneron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Jun 25 15:30:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048632, encodeId=c7f220486320e, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 10 02:30:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976875, encodeId=eaa219e6875a2, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Jan 26 07:30:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378601, encodeId=d6a313e860138, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2015-03-25 Tamikia
  2. [GetPortalCommentsPageByObjectIdResponse(id=1685566, encodeId=249d1685566d1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Mar 25 22:30:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777226, encodeId=6c151e77226ab, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Mon Nov 24 06:30:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911669, encodeId=92df1911669f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 19 02:30:00 CST 2015, time=2015-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968029, encodeId=fab5196802915, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15269, encryptionId=9e5e15269a8, topicName=Regeneron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Jun 25 15:30:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048632, encodeId=c7f220486320e, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 10 02:30:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976875, encodeId=eaa219e6875a2, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Jan 26 07:30:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378601, encodeId=d6a313e860138, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2014-11-24 FukaiBao
  3. [GetPortalCommentsPageByObjectIdResponse(id=1685566, encodeId=249d1685566d1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Mar 25 22:30:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777226, encodeId=6c151e77226ab, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Mon Nov 24 06:30:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911669, encodeId=92df1911669f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 19 02:30:00 CST 2015, time=2015-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968029, encodeId=fab5196802915, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15269, encryptionId=9e5e15269a8, topicName=Regeneron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Jun 25 15:30:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048632, encodeId=c7f220486320e, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 10 02:30:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976875, encodeId=eaa219e6875a2, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Jan 26 07:30:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378601, encodeId=d6a313e860138, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2015-01-19 snf701207
  4. [GetPortalCommentsPageByObjectIdResponse(id=1685566, encodeId=249d1685566d1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Mar 25 22:30:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777226, encodeId=6c151e77226ab, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Mon Nov 24 06:30:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911669, encodeId=92df1911669f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 19 02:30:00 CST 2015, time=2015-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968029, encodeId=fab5196802915, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15269, encryptionId=9e5e15269a8, topicName=Regeneron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Jun 25 15:30:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048632, encodeId=c7f220486320e, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 10 02:30:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976875, encodeId=eaa219e6875a2, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Jan 26 07:30:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378601, encodeId=d6a313e860138, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2015-06-25 axin009
  5. [GetPortalCommentsPageByObjectIdResponse(id=1685566, encodeId=249d1685566d1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Mar 25 22:30:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777226, encodeId=6c151e77226ab, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Mon Nov 24 06:30:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911669, encodeId=92df1911669f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 19 02:30:00 CST 2015, time=2015-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968029, encodeId=fab5196802915, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15269, encryptionId=9e5e15269a8, topicName=Regeneron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Jun 25 15:30:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048632, encodeId=c7f220486320e, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 10 02:30:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976875, encodeId=eaa219e6875a2, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Jan 26 07:30:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378601, encodeId=d6a313e860138, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2015-05-10 cy0324
  6. [GetPortalCommentsPageByObjectIdResponse(id=1685566, encodeId=249d1685566d1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Mar 25 22:30:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777226, encodeId=6c151e77226ab, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Mon Nov 24 06:30:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911669, encodeId=92df1911669f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 19 02:30:00 CST 2015, time=2015-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968029, encodeId=fab5196802915, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15269, encryptionId=9e5e15269a8, topicName=Regeneron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Jun 25 15:30:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048632, encodeId=c7f220486320e, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 10 02:30:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976875, encodeId=eaa219e6875a2, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Jan 26 07:30:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378601, encodeId=d6a313e860138, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]
    2015-01-26 linlin2312
  7. [GetPortalCommentsPageByObjectIdResponse(id=1685566, encodeId=249d1685566d1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Mar 25 22:30:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777226, encodeId=6c151e77226ab, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Mon Nov 24 06:30:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911669, encodeId=92df1911669f1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 19 02:30:00 CST 2015, time=2015-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968029, encodeId=fab5196802915, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15269, encryptionId=9e5e15269a8, topicName=Regeneron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Jun 25 15:30:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048632, encodeId=c7f220486320e, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 10 02:30:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976875, encodeId=eaa219e6875a2, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Jan 26 07:30:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378601, encodeId=d6a313e860138, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Nov 23 00:30:00 CST 2014, time=2014-11-23, status=1, ipAttribution=)]

相关资讯

埃博拉新药治愈18只染病的猴子

一种试验性药物治愈了全部18只感染埃博拉病毒的猴子。科学家们说,效果令人鼓舞,但是尚不能确定这种药对人体是否同样有效和安全。 全部18只猴子都被治愈 这种药名为ZMapp,由美国马普生物制药公司研发。 这家制药商与美国国家卫生研究院、美国军方和加拿大公共卫生局共同在猴子身上作药物试验,结果29日发表在《自然》杂志网站。 研究人员使21只试验猴子感染。大多数猴子发病,显现严重症状,包括红疹、出血和肝

哈佛尝试人体外肺部肌肉研究 望找到哮喘治疗新药

据外媒报道,现在,哮喘病患所服用的药物跟50年没什么两样。考虑到这种疾病的高发性和难治愈性,新药的研制势在必行。日前,来自哈佛大学的研究人员开始着手研究新药,并将相关研究报告发表在了Lab on a Chip上。据悉,科研人员首先将人工气道上的肌肉进行了微幅的结构改变,然后将其装载到一块玻璃芯片中。 通过向玻璃芯片内注入白介素-13(IL-13),进而诱发细胞发生哮喘反应。之后,科研人员又向当中

OPD重磅炸弹——勃林格新药Spiriva Respimat获批,将取代市场No.1药物

导读:勃林格殷格翰是呼吸疾病领域的领导者,该公司开发的COPD新药Spiriva Respimat于2007年被FDA拒绝。之后开展了全球最大的COPD临床研究,证明了疗效和安全性。近日,FDA终于批准Spiriva Respimat,该药与COPD市场中处方量排名第一的药物Spiriva HandiHaler具有相同的成分,但前者的气雾配方具有舒适性及便利性优势,尤其将使初诊COPD患者群体受益

罗氏 vs 勃林格 好戏上演——FDA同时批准2种IPF新药

过去一年多时间,InterMune公司和勃林格殷格翰(Boehringer Ingelheim)在特发性肺纤维化(IPF)新药研发领域展开了激烈的斗争,都希望各自的药物能率先赢得FDA的批准。此前,InterMune在处方药用户收费法(PDUFA)目标日期方面略占优势。但现在,FDA同时批准了2家公司的IPF药物,在抢占市场方面,双方再次站在了平等的起跑线上。 InterMune公司的IPF药物

FDA批准礼来糖尿病新药度拉糖肽(dulaglutide)上市 每周只需一次

美国食品药品监督管理局(FDA)批准礼来制药公司研发的每周一次度拉糖肽(dulaglutide)注射剂用来治疗2型糖尿病。这是在美国上市的第4个胰高血糖素样肽-1(GLP-1)受体激动剂,此前已批准诺和诺德的利拉鲁肽、阿斯利康/百石美施贵宝的艾塞那肽以及葛兰素史克的阿必鲁肽(albiglutide)。(相关报道:礼来制药降糖新药Dulaglutide非劣效于利拉鲁肽(Liraglutide) (A

开发一个新药的平均成本:全新数据26亿美元

开发一个新药到底需要花多少钱多年来一直是一个争论不休的话题。计算模式不同给出的结果会大相庭径,从少到5亿美元到福布斯的近50亿美元不等。引用最频繁的数字莫过于塔夫茨(Tufts)药物开发研究中心在2003年发表的数据8.02亿美元。然而新药开发越来越难,相应地开发成本也大幅度上升。这不仅是因为通货膨胀,监管的门槛也越来越高。比如自2000年以后血液指标逐渐成为临床开发的辅助数据,临床指标的改善